NewAmsterdam Pharma Co N.V. financial data

Symbol
NAMS, NAMSW on Nasdaq
Industry
Pharmaceutical Preparations
Location
Gooimeer 2 35, Narrden, Netherlands
State of incorporation
Netherlands
Fiscal year end
December 31
Former names
NewAmsterdam Pharma Co B.V. (to 11/22/2022)
Latest financial report
Q1 2024 - May 8, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Operating Margin -1.3K % -37391%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90M shares
Common Stock, Shares, Outstanding 89.7M shares
Entity Public Float 577M USD
Common Stock, Value, Issued 11.1M USD
Weighted Average Number of Shares Outstanding, Basic 88.4M shares +8.26%
Weighted Average Number of Shares Outstanding, Diluted 88.4M shares +8.26%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax 1.4M USD -83.8%
Research and Development Expense 42.4M USD +4.97%
Operating Income (Loss) -55.5M USD -39.2%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -93.8M USD -123%
Income Tax Expense (Benefit) 27K USD
Net Income (Loss) Attributable to Parent -93.8M USD -123%
Earnings Per Share, Basic -1.06 USD/shares -108%
Earnings Per Share, Diluted -1.06 USD/shares -108%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current 488M USD
Property, Plant and Equipment, Net 101K USD
Operating Lease, Right-of-Use Asset 38K USD
Assets 488M USD
Accounts Payable, Current 8.54M USD
Liabilities, Current 59.7M USD
Operating Lease, Liability, Noncurrent 60K USD
Liabilities 76.7M USD
Accumulated Other Comprehensive Income (Loss), Net of Tax 4.42M USD
Retained Earnings (Accumulated Deficit) -411M USD
Stockholders' Equity Attributable to Parent 412M USD +3.36%
Liabilities and Equity 488M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -54.6M USD -71.4%
Net Cash Provided by (Used in) Financing Activities 198M USD +8185%
Net Cash Provided by (Used in) Investing Activities -385K USD -5400%
Common Stock, Shares Authorized 400M shares
Common Stock, Shares, Issued 89.7M shares
Common Stock, Par or Stated Value Per Share 0.12 EUR/shares
Interest Paid, Excluding Capitalized Interest, Operating Activities 277K USD
Deferred Tax Assets, Valuation Allowance 130M USD +59.6%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.26 pure 0%
Deferred Tax Assets, Gross 130M USD +59.5%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -93.8M USD -123%
Operating Lease, Liability, Current 43K USD
Deferred Tax Assets, Operating Loss Carryforwards 75.7M USD +31%
Current Income Tax Expense (Benefit) 27K USD
Unrecognized Tax Benefits 0 USD
Current Federal Tax Expense (Benefit) 27K USD
Depreciation, Depletion and Amortization 15K USD +66.7%
Deferred Tax Assets, Net of Valuation Allowance 12K USD -55.6%
Share-based Payment Arrangement, Expense 7.92M USD +3.97%
Interest Expense 287K USD -30.2%